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The new selective access analysis system BM/Hitachi 917 was
evaluated in an international multicentre study, mainly according
to the ECCLS protocol for the evaluation of analysers in clinical
chemistry. Forty-three diå erent analytes, covering 56 diå erent
methodsÐ enzymes, substrates, electrolytes, speci￿c proteins, drugs
and urine applicationsÐ were tested in seven European clinical
chemistry laboratories. Additionally, the practicability of the BM/
Hitachi 917 was tested according to a standardized questionnaire.
Within-run CVs …median of 3 days† for enzymes, substrates and
electrolytes were <2% except for creatine-kinase MB isoform and
lipase at low concentration. For proteins, drugs and urine analytes
the within-run CVs were <4% except for digoxin and albumin in
urine. Between-day median CVs were generally <3% for
enzymes, substrates and electrolytes, and <6% for proteins, drugs
and urine analytes, except for lipase, creatine kinase and MB
isoform, D-dimer, glycosylated haemoglobin, rheumatoid factors,
digoxin, digitoxin, theophylline and albumin in urine in some
materials. Linearity was found according to the test speci￿cations
or better and there were no relevant eå ects seen in drift and carry-
over testing. The interference results clearly show that also for the
BM/Hitachi 917 interference exists sometimes, as could be
expected because of the chemistries applied. It is a situation that
can be found in equivalent analysers as well. The accuracy is
acceptable regarding a 95–105% recovery in standard reference
material, with the exception of the creatinine Jaå e ´ method. Most
of the 160 method comparisons showed acceptable agreement
according to our criteria: enzymes, substrates, urine analytes
deviation of slope §5%, electrolytes §3%, and proteins and
drugs §10%. The assessment of practicability for 14 groups of
attributes resulted in a grading of one–three scores better for the
BM/Hitachi 917 than the present laboratory situation. In
conclusion, the results of the study showed good analytical
performance and con￿rmed the usefulness of the system as a
consolidated workstation in medium-sized to large clinical chem-
istry laboratories.
Introduction
The Boehringer Mannheim/Hitachi 917 analysis system
(BM/Hitachi 917) is the most recent medium to large-
sized analysis system which was introduced to the market
by Boehringer Mannheim GmbH in December 1994.
The functionality under simulated routine conditions
was already tested during an international ® eld study
in 11 European countries [1].
In contrast to previous analysis systems of comparable
size, e.g. BM/Hitachi 717 or 737, the new 917 system
o￿ ers features making it attractive to di￿ erent purposes
and di￿ erent sections of clinical laboratories, e.g. a high
number of reagent channels, convenient reagent hand-
ling, convenient calibration, ¯ exible application settings,
short-term applications and automatic predilution. BM/
Hitachi 917 can either be used as a kind of `workhorse’
for the most often requested analytes or as a consolidated
workstation for the determination of at least 48 di￿ erent
analytes on board covering, besides the classical routine
assays, speci® c protein methods, drug methods in serum
and urine, and urine applications for enzymes, substrates,
electrolytes and proteins. The analyser is designed as a
closed system with a special reagent line and ® xed
applications; however, ® ve user-de® ned methods can be
set by the operator. A software upgrade was introduced
in April 1996; a draft version was tested at the end of the
multicentre study. This software version o￿ ers more
convenience for the operator and an enhanced data
management system, and has built-in features related to
accreditation aspects.
The versatility of the new instrument required a com-
prehensive evaluation protocol as already described for
the multicentre evaluation of BM/Hitachi 911 [2]. Seven
European laboratories participated in the multicentre
study in order to assess the analytical performance and
practicability aspects of BM/Hitachi 917. Altogether,
43 di￿ erent analytes covering 56 di￿ erent methodsÐ
enzymes, substrates, electrolytes, speci® c proteins, drugs
and urine applicationsÐ were tested in a core programme
mainly following the ECCLS guidelines [3]. In addition,
a speci® c satellite programme was carried out for speci® c
tests with less extensive evaluation experiments in order
to maintain an acceptable cost/bene® t ratio. In total,
more than 120000 individual data were generated and
statistically evaluated within a period of 7 months. Pro-
cessing and analysis of the large data volumes were
managed with the programme package CAEv (com-
puter-aided evaluation). CAEv [4] allows the de® nition
of protocols, the sample and test requests for on-line data
capture, and statistical evaluation of results. Data were
validated by the laboratories and sent via telecommuni-
cation to the central study administration.
Description of the instrument
BM/Hitachi 917 is a selective access analyser with a
capacity of at least 48 di￿ erent tests onboard out of 86
stored applications including three ISE methods. The
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gents which are distributed on any of the two reagent
disks. The theoretical test throughput is 1200 tests per
hour. Certain instrument conditions, e.g. predilution,
high sample volume pipetting, mixing of short-long-term
applications, STAT requests or additional wash steps for
the pipettors or the cuvettes needed to eliminate reagent
carry-over in certain cases lead to a reduction of the
throughput. The pipetting cycle for photometric tests is
4.5s and for the three ISE assays 18s. The software has
integrated an algorithm for throughput optimization. It
recognizes pipetting con¯ ictsÐ e.g. R2/R3 pipettingÐ
and reschedules the steps so that the additional time
needed for the con¯ ict situation is a minimum. The
bar-coded system reagents consisting of one± three vials
per test are set in any free position of the reagent disk. For
frequently requested tests, several bottles of one reagent
can be loaded into the reagent disk. An automatic bottle
changeover occurs after the ® rst bottle is registered as
empty. Application settings are loaded from application
¯ oppy disk or from application bar code sheet, both are
delivered by Roche DiagnosticsGmbH. Five applications
are user de® nable. At present, over 200 applications are
available.
Specimens are processed either from primary tubes (5±
10ml), secondary cups (2ml) or microcups (0.5ml)
positioned on a sample disk with 110 positions. Primary
tubes can be identi® ed by four di￿ erent types of bar codes
with the possibility of mixing. A standardized RS232
interface allows a bidirectional communication to a host
computer.
One hundred and sixty semi-disposable plastic cuvettes
are arranged on a rotor positioned in a waterbath of
378C. The cuvettes pass through the beam of the photo-
meter every 18s; 12 ® xed wavelengths between 340 and
800nm in mono- or bichromatic mode can be selected.
Two pipettors transfer the reagent into a cuvette. The
average reagent consumption is ¹200 ml per determina-
tion. Most of the photometric STAT results are available
10± 12 min after test request.Various measurement and
calibration procedures can be applied. The main speci-
® cations of BM/Hitachi 917 are summarized in table 1.
Materials and methods
Instruments and reagents
The methods and instruments used in this study are listed
in table 2. The same reagents were used in all evaluation
centres for each method on BM/Hitachi 917. The
reagents were available in special system packs designed
for BM/Hitachi 917. For the comparison experiments the
methods and reagent lots from the routine were used.
Calibration
During the familiarization period, a ® xed factor was
determined for the enzyme assays in three independent
calibration runs per day on three consecutive days. The
same lot of the calibrator for automated systems (Roche
Diagnostics GmbH) was used for this purpose. The ® xed
factor is the median from the median factor of the three
calibration runs per day, provided that the coe￿ cient of
variation (CV ) calculated from the nine results is less
than 3%.
The substrate, speci® c protein and drug assays were
performed with the autocalibration which is triggered
by an analyte-dependent calibration interval. For this
reason, the respective calibrator material was placed in
the cooled sample disk S2 of the instrument. The type of
calibration and the autocalibration data for all analytes
were prede® ned by Roche Diagnostics GmbH in the
chemistry parameter settings, stored on the application
¯ oppy disk.
The immunoglobulins A,G,M, transferrin and C-reactive
protein assays were calibrated according to CRM{
standardization. The ISE methods were calibrated
daily with the ISE standards and compensator. Detailed
information about the calibrator materials employed is
shown in table 9 .
Control materials
Imprecision and quality control experiments were per-
formed with lyophilized or liquid control sera from
Roche Diagnostics GmbH and control urines from Roche
Diagnostics GmbH and BioRad Laboratories; details are
shown in table 9.
For accuracy testing standard reference materials, e.g.
CRM{ material for four IFCC enzyme methods and
material from NIST} for several substrate and electrolyte
methods were used (table 9, details available on request).
A uniform procedure was applied to the treatment of
lyophilized calibrator and control material in order to
minimize matrix e￿ ects and stability problems. The
materials were reconstituted within 30min and then
stored in the dark for a further 30min before starting
the calibration runs of the experiments.
Evaluation protocol
The protocol for the analytical performance of the BM/
Hitachi 917 analysis system comprised the testing of the
quality characteristics within-run and between-day im-
precision, analytical range limits, drift over 8h, carry-
over, interferences and accuracy based on recovery in
control materials and method comparison. Forty-three
di￿ erent analytes covering 56 di￿ erent methodsÐ en-
zymes, substrates, electrolytes, speci® c proteins, drugs
and urine applicationsÐ were tested (table 2).
The total versatility of the new analysis system was
covered by a common core programme and by laboratory-
speci® c satellite programmes. The core programme com-
prised 17 analytes from the classical ® eld of clinical
chemistry and was divided into two groups consisting of
® ve laboratories each of which processed the same set of
{CRM 470 [5], BCR information, Community Bureau of Reference,
Brussels.
{BCR information, Community Bureau of Reference, Brussels.
}National Institute of Standards & Technology, O￿ ce of Standard
Reference Materials, Gaithersburg, USA.
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66Table 1. Instrument speci￿cations.
(1) Type of instrument Discrete selective multianalyser.
(2) Test channels Forty-® ve, with ISE module 48, to be increased with monoreagents.
(3) Test procedures Endpoint, endpoint with sample blank, kinetic with serum or substrate start with or without sample
blank, ® xed-time kinetic, combination of two endpoint tests, endpoint and kinetic tests, two kinetic tests
performing two tests in one cuvette, two prozone check procedures, measurement with ISE, linear
calibration and ® ve non-linear modes of calibration, autocalibration, one- and two-point recalibration,
isoenzyme calibration, serum indices indicating haemolytic, icteric and lipaemic specimens.
(4) Throughput Maximum 800 photometric tests/h, with ISE-module 1200 tests/h.
(5) Sampling system Sample disk 1 with 110 positions arranged in two concentric rings for routine and STAT samples in bar
code identi® cation mode. Up to 55 positions in the inner ring are user de® nable for STAT samples in
non-bar code mode. Sample disk 2 with 57 cooled positions for calibrators and controls, and three ® xed
positions for wash solutions.
Primary tubes from 13 to 16 mm diameter and 75 to 100mm length, secondary sample cups with 2.0ml
and microcups with 0.5ml maximum volume. Bar code identi® cation of primary tubes using codabar
NW 7, code 39, two out of ® ve interleaved and code 128. Di￿ erent codes and tube sizes are allowed
within one sample disk.
(6) Sample pipettor Two± thirty-® ve microlitres (in steps of 0.1ml), imprecision <1%; for ISE 15ml for the three
determinations of Na, K, Cl.
(7) Reagent cooling Cold water circuit, refrigerator temperature 5± 128C.
(8) Reagent bottles Seven, 20 and 70ml sizes, two reagent disks with 45 bottle positions. Disk 1 for reagent 1, disk 2 for
reagent 1 (monoreagents), 2 and 3.
(9) Reagent dispenser Two reagent pipettors for dispensing reagents 1± 3, 20± 270 ml steps in 1ml steps.
(10) Mixing procedure Two stirrers mix the reaction solution independently after addition of each reagent with additional
mixing programmable.
(11) Reaction rotor Turntable with 160 cuvettes; quarter rotation (37 cuvettes ‡4) in 4.5sˆone working cycle.
(12) Reaction cuvettes Special plastic cuvettes, semidisposable. Volume required: minimum 180ml, maximum 380ml. Optical
path length: 5mm.
(13) Reaction cycle Ten reaction times between 1 and 10min corresponding to measuring points between 4 and 34.
(14) Temperature control Waterbath, 37§ 0:18C
(15) Photometer Single-beam photometer with 12 available wavelengths: 340, 376, 415, 450, 480, 505, 546, 570, 600, 660,
700 and 800nm; mono- or bichromatic measurement with free selectable wavelength combinations.
Light source: halogen lamp. Detector: silicone photodiode.
Wavelength adjustment: ® xed, via a grating chromator, inaccuracy at 340§ 2nm and at 405±
800 § 55nm.
Half band width: 4nm in the UV range,
10nm in the visible range.
Photometric range of linearity: A ˆ 0± 3.0 at 340nm.
Photometric resolution: A ˆ 0:0002.
Photometric inaccuracy: max. 1% at 2.0 abs.
(16) Ion-selective electrodes Indirect potentiometry; ¯ ow-through electrode with liquid membrane.
Reference electrode, liquid membrane.
Dilution ratio: 1:31.
Incubation temperature: 37§ 0:18C.
Calibration: two-point with compensation.
Measuring cycle: 18s.
Measuring range in serum in urine
Na‡ 80± 180 10± 250 mmol/1
K‡ 1.5± 10 1± 100 mmol/1
Cl7 60± 120 10± 250 mmol/1
Consumption of ISE solution per sample:
Diluent: 450ml
Internal standard: 1050ml
KCl solution: 130ml.
(17) Data processing Data input: via touch screen or alpha numeric keyboard item select keys.
Data control: CRT 14 inch colour monitor.
Data output: matrix printer, 80 characters per line, 220 characters per second.
CPU with 16 MB RAM, 270 MB HD and 1 FD drive, 3.5 inches.
Interface: RS 232 C. Bidirectional link with a host computer.
(18) Water supply Internal reservoir with an external supply.
Quality: <1s.
Consumption during operation: 401/h
(19) Ambient temperature 15± 328C.
(20) Relative humidity 45± 85%.
(21) Physical dimensions Analyser unit Operation unit
Width 1.40 m 0.65 m
Depth 0.77 m 0.85m
Height 1.17 m adjustable.
(22) Weight Approx. 400kg.
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Comparison instruments and methods diå erent from H917
Study
Methods on BM/Hitachi 917 A B D E GB I NL units
ALAT Alanine aminotransferase IFCC, with PYP H717 H747 H747 H747 Chem I U/l
opt. no PYP opt.
ASAT Aspartate aminotransferase IFCC, with PYP H747 H747 H737 H747 Chem I U/l
no PYP opt. opt.
ALP_I Akaline phosphatase IFCC H747 U/l
ALP_O Alkaline phosphatase DGKCh H747 U/l
AMYLP Pancreatic ¬-amylase EPS H747 H747 H717 Chem I U/l
CNP malt.
AMYLT Total ¬-amylase EPS H747 U/l
CK Creatine kinase NAC activ. H747 H747 C. FARA H747 ELAN U/l
Sigma
CK-MB Creatine kinase, MB-isoform Immuninhibition C. FARA U/l
Sigma
GGT_I ®-Glutamyl-transferase IFCC H747 U/l
GGT_S ®-Glutamyl-transferase Szasz H717 H747 H747 Chem I U/l
LDH_O Lactate dehydrogenase DGKCh H717 H747 Chem I U/l
LDH_S Lactate dehydrogenase SFBC H747 H717 U/l
LIP Lipase Turbidimetric H717 U/l
CHOL Cholesterol CHOD-PAP H747 H747 H717 H747 Biotr. Chem I mmol/l
Abel Kend.
CREAJ Creatinine Ja￿ e Â H717 H747 H747 Chem I mmol/l
CREAP Creatinine PAP H747 mmol/l
GLU_HK Glucose HK H747 H747 C. FARA H747 Dimens. mmol/l
TP Total protein Biuret H747 H747 H737 H747 Chem I g/l
UA Uric acid PAP H717 H747 H747 H747 Chem I mmol/l
UREA Urea UV H717 H747 H747 H747 Chem I mmol/l
CA Calcium OCPC H747 H747 H717 H747 Chem I mmol/l
FE Iron Ferrozine H717 H747 H747 H747 EPOS mmol/l
LACT Lactate UV H911 mmol/l
PAP/Biom.
NA_I Sodium ISE H717 H747 H747 H747 H737 H747 Chem I mmol/l
K_I Potassium ISE H717 H747 H747 H747 H737 H747 Chem I mmol/l
CL_I Chloride ISE H717 H747 H747 H747 H737 H747 Chem I mmol/l
APOA1 Apolipoprotein A1 TIA, IFCC H717 BNA Array g/l
APOB Apolipoprotein B TIA, UFCC H717 BNA Array g/l
ASLO Antistreptolysin O LPIA BN-II IU/ml
CRP C-reactive protein TIA H717 H911 BNA H717 FLX BNA Dimens. mg/l
BNA Abbott
DDIM D-Dimer LPIA Nycocard Sclavo mg/l
FERRI Ferritin LPIA C. Core ES 700 ES 600 mg/l
HBA1C Haemoglobin A1c TIA HPLC H911 HPLC %
Shimatsu Biorad
IGA Immunoglobulin A TIA BNA Array g/l
IGG Immunoglobulin G TIA BNA Array g/l
IGM Immunoglobulin M TIA BNA Array g/l
RF Rheumatoid factor LPIA BNA BNA H717 IU/ml
TRANS Transferrin TIA H717 H911 BNA H717 Array g/l
DIG Digoxin LPIA H717 STRATUS/ mg/l
ELAN
DIGIT Digitoxin CEDIAR assay H717 mg/l
PHEBA Phenobarbital CEDIAR assay ELAN mg/l
SYVA
THEO Theophylline CEDIAR assay ELAN mg/l
SYVA
T4 Thyroxine CEDIAR assay ACS nmol/l
CIBA CORN.
A1MG ¬-1 Microglobulin TIA Ð mg/l
MAU Albumin in urine TIA RIA Ð Array mg/l
CREAJU Creatinine (in urine) Ja￿ e Â H911 C. FARA EPOS mmol/l
CREAPU Creatinine (in urine) PAP NOVA H747 mmol/l
GLUHKU Glucose (in urine) HK H911 H747 EPOS mmol/l
UA_U Uric acid (in urine) PAP H911 H747 EPOS mmol/l
UREA_U Urea (in urine) UV NOVA H911 H747 H737 EPOS mmol/l
CA_U Calcium (in urine) OCPC H911 H747 H717 EPOS mmol/l
MG_U Magnesium (in urine) Xylidyl blue H747 H717 AAS mmol/l
PHOS_U Phosphate (in urine) Molybdate, UV H911 H747 H717 EPOS mmol/l
NA_IU Sodium (in urine) ISE NOVA H911 H747 Flame Dimens. mmol/l
K_IU Potassium (in urine) ISE NOVA H911 H747 Flame Dimens. mmol/l
CL_IU Chloride (in urine) ISE NOVA H911 H747 Flame Dimens. mmol/l
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programme (® gure 1). The protocol was designed in that
way where each analyte was processed in an odd number
of laboratories so that the median of the statistics from the
individual laboratories is related to the outcome of a
single experiment. The ISE analytes were performed by
all evaluation sites. The various analytes were split
between the seven evaluation sites for the studies of
linearity, drift and sample-related carry-over. Similarly,
the testing for endogenous interferences was shared be-
tween the laboratories. Only the core programme cov-
ered the total evaluation phase with familiarization,
initial trial and main trial. The initial trial consisted of
a between-day imprecision experiment over 11 days. The
evaluation protocol of the main trial is shown in table 3.
The satellite programme contained analytes from various
laboratory segments, e.g. speci® c proteins, drugs and
urinalysis. This programme was integrated into the
main trial and included the experiments within-run
and between-day imprecision, method comparison and
in most cases analytical range limits and interference.
During a start-up meeting of the multicentre evaluation,
all evaluators agreed upon the protocol and the quality
speci® cations proposed by Boehringer Mannheim.
Software upgrade evaluation
The total evaluation of the analytical performance was
carried out with software version V1. In addition to this
evaluation a software functionality testing of the new
version V2 was performed. This new version includes
improvements of certain screen designs and new func-
tions, e.g. enhanced data management capabilities, bar
code sheets for convenient transfer of applications, cali-
brator and control material information, reagent ex-
change during operation, a new quality control
package, usage of monoreagents either on reagent disk
one or two in order to increase the number of tests on
board, and a context sensitive help system.
The evaluation protocol comprised a familiarization
phase with the new software, a within-run imprecision
experiment with two control sera and a human specimen
pool to provide the information that the new software
version shows a comparable imprecision. Routine simu-
lation experiments related to reproducibility and down-
load experiments to test comparability and functionality
testing of the bar code sheets for applications, calibrators
and control materials should prove reliability and correct
system functionality.
As for the other experiments of the study, the
de® nition and performance of the routine simulation
was carried out with the software package CAEv [10].
Reproducibility was tested in an experiment based on the
within-run imprecision concept which consisted of two
parts, a `reference’ part being performed as a usual
imprecision run with two control materials and at least
two human specimen pools in 15 repetitions, followed by
the random part with variable numbers of requests
(1± 23) per sample and variable test pattern per sample
type according to the routine situation of the laboratory
[1]. In a second simulation imprecision experiment,
provocation steps to the analytical system were
integrated, e.g. sample short, STAT sampling, reagent
interrupt, reagent bar code error, sample bar code error,
additional test selection.
In two routine download experiments, ¹100 samples
from the daily routine runs were transferred to the
BM Hitachi instrument. The sample sequence and
the results were downloaded to the CAEv database,
and a corresponding request for BM/Hitachi was
generated [1].
Assessment of reliability and practicability
For the assessment of reliability, a logbook was kept
throughout the total evaluation period (7 months, multi-
centre evaluation and software V2 testing). Any break-
down, defect, malfunction or unexpected incident of the
analysis system was recorded.
Practicability was assessed with the aid of a questionnaire
[11] comprising ¹200 questions or attributes which
covered all important aspects of an analysis system in
the clinical laboratory. The attributes were summarized
into 14 groups, as shown in ® gure 7. They were related to
the installation of the analyser, organization of work,
quality assurance and miscellaneous characteristics.
The assessment was based on a scale from 1 to 10
for the instrument under evaluation as well as for
the present laboratory situation. A score of 1 meant
unimportant, useless or poor, and a score of 10,
absolutely necessary or excellent. The meaning of score
5 was acceptable or comparable with the present
laboratory situation. Additionally, a weight factor
was assigned to each of the attributes. The factor
ranged from 0 to 3 with the following meanings: 0,
the attribute was not used during this assessment; 1, the
attribute was unimportant for the laboratory; 2, the
attribute was of general importance for the assessment;
and 3, the attribute is very important for the
evaluation site.
Figure 1. Contribution of analytes of the core programme over the evaluation sites.
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Imprecision
Within-run
On 3 days, each day one run with 21 aliquotes.
. Two control materials (serum, plasma, urine) with di￿ erent concentrations of the analyte.
. One human specimen pool at the decision level.
Between-day
. Two control materials with di￿ erent concentrations of the analyte and one human pool (deep frozen and thawed) at the decision level over 11 days
and subsequent 10 days in the main trial combining the two parts into one experiment. Precision is derived from the second of triplicate
measurements.
Drift
. Two control sera and the calibrator are determined every 30min during 8h.
. At zero hour the base value is determined as the median of triplicate measurements.
. The percentage recovery from the base value is taken as the measure for drift e￿ ects.
Linearity
Protocol is based on Ref. [3].
Mixing of a high level with a low level specimen leads to:
. a dilution series of 11 concentration steps with nine dilution steps plus two basic concentrations;
. triplicate measurements of samples from the 11 concentration steps and calculation of the median for each step;
. calculation of the regression line (P/B-regression [7] using values of ® ve concentrations, the range of which is assumed to be linear;
. calculation of the target values for all concentration steps from the regression line.
Carry-over
Sample-related
Model of Broughton [8]
. Measurements of ® ve aliquots of a high-concentration sample …h1 ...h5†.
. Followed by measurements of ® ve aliquots of a low-concentration sample …l1 ...l5†.
The experiments are repeated 10 times.
If a carry-over e￿ ects exists, the l1 is the most in¯ uenced, l5 the least in¯ uenced aliquot.
The sample-related carry-overÐ median …l1± l5†Ð is compared with the imprecision of the low-concentration sample.
Reagent-dependent
Assay A in¯ uences assay B.
. Carry-over caused by the cuvettes.
Test A is pipetted into 21 cuvettes and the analyser is stopped. Assay B is performed in 42 cuvettes; the ® rst 21 determinations may be in¯ uenced by
assay A, the last 21 determinations are unin¯ uenced. The di￿ erence of the medians of both series is the carry-over.
. Carry-over caused by reagents probes and stirrers.
Assay B is carried out 21 times. In a second step, test A and B are requested 21 times. The carry-over is the di￿ erence between the medians of both
series.
The carry-over e￿ ects are compared with the imprecision and the diagnostic relevance of assay B.
Interference
Protocol of Glick [9].
A serum with concentrations at the relevant decision level is spiked with the interfering substance, and a dilution series of 10 dilution steps is prepared
with the same baselinee serum. The di￿ erent analytes are measured in triplicate. The concentration of the interfering substance is related to the serum
index of the instrument. The percentage recovery of the baseline value from the corresponding analyte is calculated for each dilution step.
The serum indices characterize the specimens according to haemolytic, icteric and lipaemic interference. The index for bilirubin and haemoglobin
corresponds approximately to the concentration of these interferents, and the lipaemic index is related to the turbidity at 660/700nm expressed at
absorbance£10.000.
Accuracy
Calibration.
. The calibrators of BM/Hitachi 917 and of the comparison instrument are both run on each instrument.
Quality control in two control materials.
. Assigned values for several substrate and electrolyte methods are related to reference methods.
. Median, calculated from the second of triplicate measurements on 21 days.
Interlaboratory survey.
. One control material with concentrationsnot known tothe evaluators; assigned valuesfor several substrate methodsare related toreference methods.
. Median, calculated from the second of triplicate measurements over 10 days.
Standard reference material.
. For certain enzymes, substrate and electrolyte methods analysed on 1 day in triplicate measurements.
Method comparison in fresh human specimens.
. Five± 15 specimenspr day depending on analytesfor 10 days on BM/Hitachi 917 and on the comparison instruments. The total number of specimens
cover the entire analytical range.
. Comparison of the methods by calculation of the Passing/Bablok regression line [7].
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The agreed acceptance criteria for imprecision are set up
with a view to ful® lling requirements of the daily
laboratory routine and statistical error propagation
[12]; they are listed in table 4. Additionally, imprecision
is judged on criteria based on within-subject biological
variation according to Fraser et al. [13, 14]
The quality speci® cations for the within-run CV of
the enzyme and substrate methods are derived from
error propagation as shown in Ref. [12]. Due to the
daily variation of the analysis system, one should expect
a higher CV compared to the within-run CV. The
ISE methods in general show a better reproducibility
than the photometric assays. Drug and speci® c protein
assays have very often low analytical sensitivity and
many of them are calibrated by a non-linear mode;
therefore, a CV twofold higher than that of the
classical photometric determinations is reasonable.
Because urine applications are performed in several
cases with a sample predilution and are calibrated with
the serum application volume ratio, which is not
adequate for urine concentrations, an elevated CV can
be expected.
The measuring range of a method should cover the
greatest part of the physiological and pathophysiological
range so that rerun analyses rarely will be necessary. In
the upper range, a method is de® ned to be linear if the
di￿ erences between the measured values and the target
values from the dilution seriesare below 5%. In the lower
range, the absolute di￿ erences are judged with respect to
the diagnostic relevance. Methods with multipoint cali-
bration are regarded as linear if a change in the target
concentration leads to a corresponding change in the
measured concentration [6].
Drift e￿ ects are not accepted if a systematic deviation
from the initial value exceeds 3%.
Carry-over e￿ ects are assessed on the basis of the ob-
served change in recovery of an analyte. Instead of
adapting an individual deviation for each analyte, the
within-run imprecision system performance is used which
Table 4. Acceptance limits for imprecision.
Within-run Between-day
Analyte group CV(%) CV(%)
Enzymes 2 3
Substrates 2 3
ISE methods 1 2
Speci® c proteins 4 6
Drugs 4 6
Urine methods 4 6
Figure 2. Within-run imprecision, frequency distribution of all CVs.
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71means that a change of less than twice the standard
deviation is accepted.
According to Glick et al. [9], a method is resistant to
interference if the deviation between the baseline value
and the measured value is less than 10%.
Accuracy is assessed in recovery experiments performed
with certi® ed reference materials, with control materials
of which the assigned values are related to reference
methods, and in method comparison experiments in
which the comparison method is a reference method.
A relative accuracy is obtained by the usual method
comparison experiments related to the routine methods
of the laboratory.
Results of the recovery experiments are de® ned as being
acceptable if their deviations from the target values do
not exceed more than § 5% for enzymes and substrates,
and §3% for the electrolyte methods calcium, chloride,
potassium and sodium.
For the method comparisons, the acceptable range is
de® ned for the slope and intercept of the regression
equation. The slope should not deviate more than
§5% from the identity line and the intercept should
Table 5. Within-run imprecision in a normal human serum, plasma or urine pool …n ˆ 21†.
Analyte Unit Concentration CV (%)
Alanine aminotransferase U/l 49.4 0.5
Aspartate aminotransferase U/l 44.9 1.0
Alkaline phosphatase U/l 102 0.5
¬-Amylase total U/l 168 1.0
¬-Amylase pancreatic U/l 79.2 1.1
Creatine kinase U/l 163 0.6
Creatine kinase MB U/l 14.4 5.8
®-Glutamyltransferase U/l 42.2 1.2
Lactate dehydrogenase U/l 446 0.3
Cholesterol mmol/l 5.3 1.0
Creatinine mmol/l 115 0.9
Glucose mmol/l 6.32 1.0
Total protein g/l 68.8 1.0
Uric acid mmol/l 300 0.6
Urea mmol/l 8.65 0.7
Calcium mmol/l 2.33 0.6
Iron mmol/l 13.7 2.0
Lactate mmol/l 2.19 0.4
Sodium mmol/l 143 0.4
Potassium mmol/l 4.63 0.3
Chloride mmol/l 106 0.9
Apolipoprotein A-1 g/l 1.29 1.4
Apolipoprotein B g/l 1.05 0.5
Antistreptolysin O IU/ml 85 1.8
D-dimer mg/l 1.5 1.5
C-reactive protein mg/l 7.6 3.0
Ferritin mg/l 77.6 1.7
Haemoglobin A1c % 5.94 2.8
Immunoglobulin A g/l 2.8 1.0
Immunoglobulin G g/l 11.27 1.4
Immunoglobulin M g/l 1.19 0.8
Rheumatoid factor IU/ml 22.9 3.5
Thyroxine nmol/l 104 2.2
Transferrin g/l 3.2 0.7
Digoxin mg/l 0.74 4.5
Digitoxin mg/l 17.9 3.1
Phenobarbital mg/l 24.6 0.8
Theophylline mg/l 7.4 1.7
Albumin in urine mg/l 16.3 3.0
¬-1-Microalbumin mg/l 7.2 2.2
Creatinine in urine mmol/l 13 0.6
Glucose in urine mmol/l 17.2 0.8
Uric acid in urine mmol/l 2.5 1.4
Urea in urine mmol/l 283 0.9
Magnesium in urine mmol/l 3.7 1.4
Sodium in urine mmol/l 43 0.5
Potassium in urine mmol/l 68 0.3
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72be less than §5% of the diagnostically important
decision level. Due to the lower analytical sensitivity
and the non-linear calibration mode of many of
the homogeneous immunoassays, the acceptance
limits for the method comparisons must be set higher.
A deviation of §10% for the slope is tolerated by
the evaluators. Likewise, a deviation of §10% from the
decision or the detection limit is acceptable.
Table 6. Linearity.
Analyte/Method Unit Lab Concentration tested Linearity found
Alanine aminotransferase U/l 3 270 270
BM* 440 310
Aspartate aminotransferase U/l 3 340 340
BM* 550 550
Alkaline phosphatase/IFCC U/l 4 770 770
BM* 2500 2500
¬-Amylase total U/l 6 1500 1500
BM* 3200 3200
¬-Amylase pancreatic U/l 7 2100 2100
Creatine kinase U/l 2 1750 1750
Creatine kinase MB U/l 5 230 230
®-Glutamyltransferase/IFCC U/l 4 900 900
BM* 1600 1600
®-Glutamyltransferase/Szasz U/l 7 1200 1200
BM* 1800 1800
Lactate dehydrogenase/opt. U/l 3 1060 1000
BM* 1600 1300
Lactate dehydrogenase/SFBC U/l 4 600 600
BM* 1900 1900
Cholesterol mmol/l BM* 22.9 22.9
Creatinine mmol/l BM* 2100 2000
Glucose mmol/l 6 53 53
Total protein g/l 5 115 115
BM* 190 190
Uric acid mmol/l 1 1550 1550
BM* 1800 1800
Urea mmol/l 1 44 44
BM* 70 70
Calcium mmol/l 6 6.3 5.9
Iron mmol/l BM* 314 314
Lactate mmol/l 2 16 15
Sodium mmol/l 5 150 150
BM* 300 300
Potassium mmol/l 5 6.3 6.3
BM* 15 15
Chloride mmol/l 5 112 112
BM* 270 270
Antistreptolysin O IU/ml 1 580 560
C-reactive protein mg/l 4 180 180
Ferritin mg/l 3 400 400
Immunoglobulin A g/l 2 8.6 8.6
Immunoglobulin G g/l 2 40 40
BM* 56 50
Immunoglobulin M g/l 2 7.5 7.5
BM* 10 10
Thyroxine nmol/l 5 248 248
Transferrin g/l 3 3.2 3.2
Digoxin mg/l 6 7.5 7.5
Digitoxin mg/l 1 44 44
Albumin in urine mg/l 3 370 370
¬-1-Microalbumin mg/l 3 94 94
Calcium in urine mmol/l 7 12 12
Creatinine in urine mmol/l 7 32 32
Uric acid in urine mmol/l 7 17 17
Urea in urine mmol/l 7 950 950
Sodium in urine mmol/l 7 220 220
Potassium in urine mmol/l 7 93 93
Phosphorus in urine mmol/l 7 100 100
* Evaluation data from Boehringer Mannheim.
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cannot be achieved according to the above-mentioned
criteria. Due to the narrow physiological range, espe-
cially of sodium and chloride, a relatively large con-
® dence interval for the regression line is obtained.
Therefore, method comparisons are judged by the con-
centration range in which the di￿ erence between the
methods is less than 3%.
Sodium: 120± 170 mmol/l.
Potassium: 2± 10mmol/l.
Chloride: 80± 130 mmol/l.
Results
Imprecision
Acceptance criteria were based on statistical error pro-
pagation [12] (see table 4) . Within-run distribution of all
CVs measured for all analytes are shown in ® gure 2,
additionally the median CVs for within-run imprecision
in a human serum and urine pool are presented in table 5.
The medians of all analytes met the acceptance criteria,
except for creatine kinase MBisoform (CV of 5.8% in the
human serum pool), lipase (CV of 5.2% in the human
Figure 3. Between-day imprecision, frequency distribution of all CVs.
Table 7. Sample related carry-over.
Median Median Ratio Median SD
Analyte Unit Lab high conc. low conc. h : l I1 ¡ I5 I3;I4;I5
Amylase total U/l 6 10263 96 107 0 1.1
Creatine Kinase U/l 7 3606 55 65.6 1 0.6
Ferritin mg/l 1 7300 17.8 410 70.3 0.5
Ferritin mg/l 7 >900 80 >11 0.7 1.3
Albumin U/S mg/l 3 40000 27.2 1470 5.3 0.22
Creatinine U/S mmol/l 3 15.2 0.12 127 0 0.003
Creatinine U/S mmol/l 2 25.1 0.08 331 0 0.001
Creatinine U/S mmol/l 5 20.1 0.1 201 0 0.003
Creatinine U/S mmol/l 7 22.5 0.11 201 0 0.001
Potassium U/S mmol/l 3 150 3.89 38 0.05 0.012
Potassium U/S mmol/l 3 150 4.02 37 0.04 0.009
Potassium U/S mmol/l 5 124 4.14 30 0.03 0.027
Uˆurine; Sˆserum.
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74serum pool), digoxin (4.5% in the human serum pool)
and albumin in urine (4.3%). In individual control sera
results exceeding the acceptance limits were obtained for
ALAT (2.1%), creatinine (2.4%), chloride (2.8%) and
glycosylated haemoglobin (4.3%).
The distribution of all CVs measured in all sera for
between-day imprecision are presented in ® gure 3. The
medians met the de® ned quality speci® cations for the
majority of analytes. The acceptance limits for median
CV were exceeded for creatine kinase (3.3% in the
human serum pool), creatine kinase MB isoform (9.4%
in the human serum pool), lipase (4.5% in control serum
2 and 4.8% in the human serum pool), D-dimer (6.6% in
control serum 1), glycosylated haemoglobin (6.9% in
control serum 2), rheumatoid factors (9.8% in control
serum 2), digoxin (7.8% in the human serum pool),
digitoxin (6.6% in control serum 1 and 8.4% in the
human serum pool), theophylline (6.7% in the human
serum pool) and albumin in urine (up to 23% below
10mg/l). In individual control sera, results exceeding the
quality speci® cations could be seen for alkaline phospha-
tase (3.6%) and chloride (up to 3.2%).
Additionally, the data related to within-day imprecision
are judged by the maximum allowable imprecision based
on within-subject biological variation according to Fraser
et al. [13, 14]. Median CVs for between-day imprecision
were within these criteria for all analytes except for
sodium (1.0%), chloride (1.6%), digoxin (8.4%) and
phenobarbital (3.9%).
Analytical range limit
In table 6, the results of the assessment of linearity are
presented. A wide linearity range was obtained for all
clinical chemistry analytes, covering the greatest part of
the clinical relevant range. All results were within the
speci® cations of the manufacturer.
Drift
Drift e￿ ects were not accepted if a systematic deviation
from the initial value exceeded 3%. No drift e￿ ects were
observed over an 8h period in any of the methods tested.
Carry-over
In table 7, the results of the sample carry-over testing are
presented. If the carry-over isless than twice the standard
deviation of the analyte tested, the results are judged as
being acceptable. As can be seen from table 7, all results
are acceptable except albumin in urine. The carry-over
of 5.3mg/l is not only exceeding twice the standard
deviation (0.44 mg/l), but also the criteria of the
manufacturer (1mg/l). Considering the reagent-
dependent carry-over, there was a signi® cant probe
carry-over in two out of seven laboratories (ALAT/
LDH) and a cuvette carry-over (TG/LIP) in one out of
seven laboratories. This could be explained by sub-
optimal wash procedures in the analysers concerned.
Interferences
According to Glick et al. [9], a method is resistant to
interferences if the deviation between the baseline value
and the measured value is below 10%. The methods not
ful® lling these criteria are presented in table 8.
Accuracy
The results of the recovery experiments in the certi® ed
reference materials are presented in ® gure 4. As can be
seen, the results for enzymes (95.3± 103.9%) are all within
the 95± 105% range. Considering the substrates and
electrolytes there was a good performance except for
creatinine, urea and chloride. Creatinine showed a
recovery up to 120% in SRM 909 a-1 and a recovery
of only 93% in SRM 909 a-2. The recovery for urea is
only slightly above the tolerance limits (105.8%) and
therefore not very relevant. The recovery for chloride
is signi® cantly di￿ erent between the two laboratories
concerned. This is possibly caused by a lot-to-lot
variability.
The results for the recovery in the interlaboratory survey
are presented in ® gure 5. The analytes outside the
recovery limits for the reference materials also show
results exceeding the limits in the interlaboratory survey.
Additionally, results for alanine aminotranferase, aspar-
tate aminotranferase, pancreatic amylase, cholesterol and
glucose were not within the quality speci® cations for all
laboratories.
Method comparison
In total, 160 method comparison studies were performed,
using fresh human sera or urines; representative regres-
sion equations of each group of analytes are shown in
® gure 6. Additional regression data are available on
request.
For cholesterol and creatinine, the results are compared
to both routine and reference methods. As can be seen
from ® gure 6, cholesterol meets the acceptance criteria if
Table 8. Endogeneous interferences.
Analyte Haemolysis Icterus Lipaemia
Alanine aminotransferase "
Aspartate aminotransferase """* " "
¬-Amylase total "
¬_Amylase pancreatic "
Creatine kinase "" "
Creatine kinase MB ""
®-Glutamyltransferase "" "
Lipase ""
Lactate dehydrogenase """*
Cholesterol "
Creatinine PAP """
Total protein " "
Uric acid ""
Calcium "
Iron ""*
Potassium ""*
D-dimer ""
C-reactive protein "
* Present in erthyrocytes.
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75compared to the Abell Kendall reference method, but
creatinine on the BM/Hitachi 917 is inaccurate if
compared to the HPLC reference method. For all other
analytes, regression data do show an acceptable
regression equation with the exception of ASAT,
ALAT, sodium, chloride and glycosylated haemoglobin
in some laboratories.
Reliability
Reliability during the evaluation phase was rated with
the aid of a logbook in which all aspects of interest were
recorded.
As a result of all logbooks, only a few problems or
incidents have to be mentioned here. In one laboratory,
the liquid level detection for reagent pipetting appeared
to work incorrectly just before a reagent bottle change-
over leading to an incorrect result without any ¯ ag.
This error could not be reproduced during the further
study.
The motor of the operation unit stand was defect at one
site. As a consequence, the screen could not be adjusted
correctly to the height of the operator. The defect was
repaired by exchanging the motor. A further laboratory
reported an alarm of abnormal ISE syringe movement
which was observed only once.
Assessment of practicability
The practicability of the BM/Hitachi 917 was judged in
comparison with the present situation in the evaluating
laboratories. The median of all laboratories was calcu-
lated from the mean of all scores obtained from each
group of attributes. These results are shown in ® gure 7.
More detailed information on the distribution of scores in
relation to the main topics is given in ® gure 8.
Discussion
The new selective access analysis system BM/Hitachi 917
was evaluated in an international multicentre study,
mainly according to the ECCLS criteria for the evalua-
tion of analysers in clinical chemistry. Forty-three di￿ er-
ent analytes, covering 56 di￿ erent methodsÐ enzymes,
substrates, electrolytes, speci® c proteins, drugs and urine
applicationsÐ were tested in seven European clinical
chemistry laboratories. Additionally, the practicability
of the BM/Hitachi 917 was tested according to a
standardized questionnaire.
Figure 4. Accuracy CRM/NIST.
Figure 5. Interlaboratory survey.
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77A good performance was found for most of the analytes in
all laboratory sections using di￿ erent sample materials of
serum, plasma and urine. Although some of the analytes
did not ful® l the acceptance criteria, none could be rated
as unacceptable. With more than 120000 individual
data, it isimpossible to discuss all the results, we therefore
selected mainly the results outside the acceptance criteria
for discussion.
Regarding the analytical evaluation, and starting with
the precision study, we found very satisfying results
overall with only a few exceptions (see tables 4 and 5).
In the enzyme, substrate and electrolyte section, we only
found twooutlying results with the human pool sample in
measuring the within-run imprecision, maybe because of
the (low) concentration of creatine-kinase MBand lipase.
For proteins, drugs and urine analytes, all within-run
median CV results were lower than 4%, except for
digoxin (4.5%) and albumin in urine (4.3%)
Concerning the between-day CVs, here too, very few
results exceeding the acceptance limits were observed, i.e.
lipase, creatine-kinase and MB isoform, D-dimer, glyco-
sylated haemoglobin, rheumatoid factor, digoxin, digi-
toxin, theophylline and albumin in urine in some
materials. In all situations, the comparison methods
gave equivalent results with the exception of glycosylated
haemoglobin.
Comparing the results of the between-day imprecision
measurements with the Fraser criteria based on within-
subject biological variation [13, 14], it is justi® ed to say
that the BM/Hitachi 917 achieved these criteria for all
analytes except sodium, chloride, digitoxin and pheno-
barbital. For sodium and chloride it should be stated that
the biological varition is that low that no available
technology of today can ful® l these criteria.
The linearity, drift and carry-over study showed results
all satisfying the test speci® cations. One exception is the
carry-over e￿ ect of 5.3mg/l albumin in urine, which is
beyond the acceptance limits of 1.0mg/l speci® ed by the
manufacturer. Measurements performed on two instru-
ments at Boehringer Mannheim resulted in a carry-over
e￿ ect of 1.7mg/l, which still requires the use of a evasion
procedure.
The interference results are given in table 8, clearly
showing that also for the BM/Hitachi 917 interference
exists sometimes, as could be expected because of the
chemistries applied. It is a situation that can be found in
equivalent analysers as well [2].
The method comparisons were often performed with
other Hitachi instruments except for the exoteric tests.
Most of the 160 comparisons showed acceptable agree-
ment. Nevertheless, some deviations were found, also
caused by discrepancies in the evaluation group methods.
Striking examples in this respect are ASAT, ALAT,
chloride, sodium and HbA1c (results not shown). The
question arises whether the tolerance limits (see Intro-
duction) are applicable here.
Further, we want to point out some exceptional results. It
was, e.g. remarkable that creatinine deviated in the
Figure 7. Assessment of practicability (median of scores) .
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78comparison with the HPLC reference method (see ® gure
6). This deviation was also found in the NIST materials.
According to the information of the manufacturer, this
problem is under study now. C-reactive protein also
showed a remarkable picture: results lower than
100mg/l showed a di￿ erent regression equation from
results higher than 100mg/l (see ® gure 6). We have no
explanation for this phenomenon. The regression equa-
tions and ® gures of all additional analytes are available
on request.
In a multicentre evaluation, usually the main interest is
the evaluation of the analytical performance. Additional
to that performance, we thoroughly tested reliability and
practicability of the BM/Hitachi 917 as well. Particulary
in those stages of the evaluation, the analyser appeared to
be a multi-purpose analyser with bene® ts exceeding those
of comparable analysis systems. As can be seen from
® gure 7, the assessment of practicability for 14 groups
of attributes resulted in a grading of one± three scores
better for BM/Hitachi 917 than the present laboratory
situation.
The system o￿ ers features making it attractive to di￿ er-
ent purposes and di￿ erent sections in clinical chemistry.
It can either be used as a high-throughput analyser for
the basic clinical chemistry tests, or as a consolidated
workstation for the determination of at least 48 di￿ erent
analytes (on board), covering besides the classical routine
assays, speci® c protein methods, drug methods in serum
and urine, and urinalysis applications for enzymes, sub-
strates, electrolytes and proteins.
In the opinion of the authors, laboratory consolidation in
combination with laboratory automation is the future of
clinical chemistry. The BM/Hitachi 917 therefore can not
only be seen as a valuable analyser for the laboratories of
today, but also ® ts in the organizational structures of the
future.
Notes
(1) Most of the practical work was performed during
1996, part of it in early 1997.
(2) Despite the 1998 takeover of Boehringer Mannheim
by Roche, we used the term BM/Hitachi 917 because
of its wide international acceptance.
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